These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1009 related items for PubMed ID: 7555472

  • 1. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC, Tsang LW, Sorensen JP, Cockram CS.
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [Abstract] [Full Text] [Related]

  • 2. Comparison of different insulin regimens in elderly patients with NIDDM.
    Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ, Menheere PP, Nieuwenhuijzen Kruseman AC.
    Diabetes Care; 1996 Dec; 19(12):1326-32. PubMed ID: 8941458
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.
    Cusi K, Cunningham GR, Comstock JP.
    Diabetes Care; 1995 Jun; 18(6):843-51. PubMed ID: 7555511
    [Abstract] [Full Text] [Related]

  • 4. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.
    Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins PE.
    Diabetes Care; 1995 Aug; 18(8):1183-6. PubMed ID: 7587856
    [Abstract] [Full Text] [Related]

  • 5. Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure.
    Soneru IL, Agrawal L, Murphy JC, Lawrence AM, Abraira C.
    Diabetes Care; 1993 Jun; 16(6):896-901. PubMed ID: 8325203
    [Abstract] [Full Text] [Related]

  • 6. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS.
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [Abstract] [Full Text] [Related]

  • 7. A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients.
    Skillman CA, Raskin P.
    Diabetes Care; 1997 Apr; 20(4):591-6. PubMed ID: 9096985
    [Abstract] [Full Text] [Related]

  • 8. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [Abstract] [Full Text] [Related]

  • 9. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effects on serum lipids, lipoproteins and apoproteins.
    Vaverková H, Chlup R, Ficker L, Novotny D, Bartek J.
    Exp Clin Endocrinol Diabetes; 1997 May; 105 Suppl 2():74-7. PubMed ID: 9288551
    [Abstract] [Full Text] [Related]

  • 10. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial.
    Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M.
    Ann Intern Med; 1999 Mar 02; 130(5):389-96. PubMed ID: 10068412
    [Abstract] [Full Text] [Related]

  • 11. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.
    Clin Ther; 2007 Nov 02; 29(11):2349-64. PubMed ID: 18158076
    [Abstract] [Full Text] [Related]

  • 12. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.
    Diabetes Care; 1998 Jan 02; 21(1):87-92. PubMed ID: 9538975
    [Abstract] [Full Text] [Related]

  • 13. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
    Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN.
    Diabet Med; 2000 Jan 02; 17(1):40-7. PubMed ID: 10691158
    [Abstract] [Full Text] [Related]

  • 14. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
    Clauson P, Karlander S, Steen L, Efendic S.
    Diabet Med; 1996 May 02; 13(5):471-7. PubMed ID: 8737030
    [Abstract] [Full Text] [Related]

  • 15. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S, Chen M, Chen W, Lin K, Mu P, Zhu B, Xu W, Wang M, Weng J, Zeng L.
    J Diabetes Res; 2018 May 02; 2018():2791584. PubMed ID: 30420969
    [Abstract] [Full Text] [Related]

  • 16. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
    Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT.
    Diabetes Care; 1997 Apr 02; 20(4):597-606. PubMed ID: 9096986
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
    DeFronzo RA, Goodman AM.
    N Engl J Med; 1995 Aug 31; 333(9):541-9. PubMed ID: 7623902
    [Abstract] [Full Text] [Related]

  • 18. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK.
    Diabetes Care; 1998 Apr 31; 21(4):574-9. PubMed ID: 9571345
    [Abstract] [Full Text] [Related]

  • 19. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.
    Clin Ther; 2007 Nov 31; 29(11):2374-84. PubMed ID: 18158078
    [Abstract] [Full Text] [Related]

  • 20. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.
    Clin Ther; 2011 Dec 31; 33(12):1932-42. PubMed ID: 22078152
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.